Neurogene Inc.
Neurogene, Inc. (Nasdaq: NGNE) is a clinical-stage biotechnology company developing genetic medicines for rare, severe neurological diseases. Its lead candidate, NGN-401, is an adeno-associated virus gene therapy in Phase 3 development for Rett syndrome; it uses the company’s EXACT technology, designed to regulate… From the company’s description.
In fiscal 2025, Neurogene Inc. reported a net loss of $90.35M. Operations used $77.17M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Neurogene Inc. does
In the company’s own words
Neurogene, Inc. (Nasdaq: NGNE) is a clinical-stage biotechnology company developing genetic medicines for rare, severe neurological diseases. Its lead candidate, NGN-401, is an adeno-associated virus gene therapy in Phase 3 development for Rett syndrome; it uses the company’s EXACT technology, designed to regulate therapeutic gene expression, and is administered by intracerebroventricular infusion. Neurogene also has early-stage discovery programs for other potential indications and previously developed NGN-101 for CLN5 Batten disease, a program it is evaluating for possible next steps. The company collaborates with the University of Edinburgh on research and pipeline development, including work related to EXACT. Neurogene operates an in-house current good manufacturing practices facility that produces clinical material and supports process and analytical development. It has no products approved for commercial sale and has not established a commercial organization or distribution capabilities. As of March 16, 2026, Neurogene had 131 full-time employees.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1404644
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Neurogene Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Neurogene Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Neurogene Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Neurogene Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Neurogene Inc.'s last four quarterly filings that the numbers alone won't show?”